Abstract:OBJECTIVES:The expression level of Ubiquitin-conjugating enzyme E2T (UBE2T) is upregulated in various types of human tumors. We explored the correlation and regulatory mechanism of UBE2T in the development of colorectal cancer (CRC).METHODS:Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to examine the expression of UBE2T in the CRC tissues and cell lines. Immunohistochemical staining, spearman correlation analysis, and Kaplan Meier-survival analysis were used to demonstrate the correlation between UBE2T high expression level and the clinical characteristics of malignant patients and the overall survival. The proliferation, apoptosis, migration and invasion of CRC cells were analyzed by cell transfection, MTT, colony formation, scratch assay, transwell, and flow cytometry. Furthermore, the expression of cell proliferation and apoptosis related proteins and ubiquitination of p53 were detected by western blot.RESULTS:UBE2T was up-regulated in CRC tissues and cell lines, and high expression level of UBE2T was correlated with the clinical characteristics of malignant of CRC patients (P<0.05), and patients with high expression level of UBE2T had lower overall survival (P=0.0455). In addition, UBE2T could promote the growth, proliferation, invasion and metastasis of CRC cells and inhibit the apoptosis. At the same time, knockdown of UBE2T inhibited the growth of transplanted tumor in mice of subcutaneous CRC model. Moreover, our experimental results proved that UBE2T regulated the expression of downstream related proteins through ubiquitination of p53 protein to promote the occurrence and development of CRC.CONCLUSION:Our study elucidated that high expression of UBE2T would enhance the development of CRC, and then further explored its molecular mechanism both in vitro and in vivo. The results indicated that UBE2T facilitated ubiquitination and degradation of p53, which predicts the possibility of UBE2T as one of molecular diagnosis markers, prognostic indicators and therapeutic drug targets of CRC patients.

Alteration of tumor spectrum by ISGylation in p53-deficient mice.

Deficiency Of A Potential 3p21.3 Tumor Suppressor Gene Ube1l (Uba7) Does Not Accelerate Lung Cancer Development In K-Ras(La2) Mice

Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome

Regulation Of P53 Level By Ube4b In Breast Cancer

Hematopoietic Cells from Ube1L-deficient Mice Exhibit an Impaired Proliferation Defect under the Stress of Bone Marrow Transplantation.

Ser18 and 23 Phosphorylation is Required for P53-Dependent Apoptosis and Tumor Suppression

Inhibition of USP14 Deubiquitinating Activity As a Potential Therapy for Tumors with P53 Deficiency

Treatment with B-Ap15 to Inhibit UCHL5 and USP14 Deubiquitinating Activity and Enhance P27 and Cyclin E1 for Tumors with P53 Deficiency

The Janus Face of P53-Targeting Ubiquitin Ligases

Usp4 Inhibits P53 Through Deubiquitinating and Stabilizing Arf-Bp1

Reduction of P53 by Knockdown of the UGT1 Locus in Colon Epithelial Cells Causes an Increase in Tumorigenesis.

Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment

p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation

UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination

The Ubiquitin Peptidase Uchl1 Induces G0/G1 Cell Cycle Arrest And Apoptosis Through Stabilizing P53 And Is Frequently Silenced In Breast Cancer

Ubiquitin-conjugating Enzyme E2T(UBE2T) Promotes Colorectal Cancer Progression by Facilitating Ubiquitination and Degradation of P53.

The SWIB/MDM2 motif of UBE4B activates the p53 pathway.

Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity.

Over-expression of Small Ubiquitin-Related Modifier-1 and Sumoylated P53 in Colon Cancer.

UDP‐glucuronosyltransferase 1 (UGT1) Knockdown in Colon Epithelial Cells Causes Inactivation of P53 Mediated Apoptosis and Increases Colon Tumorigenesis (LB599)

P53 Regulation by Ubiquitin and Ubiquitin-Like Modifications